Aurobindo Pharma Ltd

IN

ARBN

Health Care

1076.25 ₽

Current price

Hold
1076.25 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    618 / 1328

  • Position in country

    2090 / 4091

  • Net income margin, %

    12.7

    2.8

  • EBITDA margin, %

    21.7

    10.8

  • Revenue CAGR 3Y, %

    2.4

    8.5

  • Revenue Y, % chg

    11.2

    0.5

  • P/E

    23

    22.7

  • P/BV

    2.2

    1.5

  • P/S

    2.2

    2.3

  • EV/S

    2.2

    2.4

  • EV/EBITDA

    12.3

    7.4

  • Average Analyst recommendation

    Hold

    Hold

  • Average upside forecasts, %

    5.6

    51.3

  • Forward P/E

    17

    15.6

  • Dividend Yield, %

    0.4

    1.7

  • Forward Dividend Yield, %

    0

    0.2

  • Expected dividend per share

    0

    0

  • Dividend Ex Date

    2024-02-20

Get an analytical review of this company

Competitors

Ranks

  • Sun Pharmaceutical Industries Ltd

    00%

  • Cipla Ltd

    00%

  • Torrent Pharmaceuticals Ltd

    00%

  • Zydus Lifesciences Ltd

    00%

  • Dr Reddy's Laboratories Ltd

    00%

  • Alkem Laboratories Ltd

    00%

  • Aurobindo Pharma Ltd

    00%

  • IPCA Laboratories Ltd

    00%

  • Lupin Ltd

    00%

  • Mankind Pharma Ltd

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    India

  • Sector

    Health Care

  • Industry group

    Pharmaceuticals, Biotechnology & Life Sciences

  • Industry

    Pharmaceuticals

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    7654

  • Ticker

    ARBN.NS

  • ISIN

    INE406A01037

  • IPO date

    1995-01-19

  • Availability on Russian exchanges

    No

  • Reporting for

    2024-02-10

  • Date fact. publication of reports

    2023-12-31

Company Description

Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs). Its product portfolio is spread over seven therapeutic/product areas, including antibiotics, anti-retrovirals, cardiovascular, central nervous system, gastroenterologicals, anti-allergies and anti-diabetics. It is engaged in developing a range of oncology and hormonal products. It is also developing inhalation and dermatology products, such as pressurized metered-dose inhaler (pMDI). It markets its products through chain stores in the United States. It has developed over three injectable penem products. The Company, through its subsidiary, manufactures and sells nutritional supplements. It has over 10 manufacturing units and approximately two research and development centers. The Company, in addition to marketing its products domestically, also markets its products globally in over 150 countries.